Author of

• 32067

  +

  EP1.11 - Screening and Early Detection (ID 201)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Screening and Early Detection
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32074

    +

    EP1.11-07 - Development of a Chromosome Instabilities in Plasma Cell-Free DNA Assay for Early Lung Cancer Detection and Treatment Response Monitoring (ID 2126)

    08:00 - 18:00  |  Author(s): Wei Yin
    • Abstract
    • Slides

    Background
    

    Background: Chromosomal instability (CIN) is one of the hallmarks of cancer. Tumor cells keep shedding DNA into blood stream which provides an opportunity for CIN analysis. Here we present a retrospective study to investigate the potential of CIN in plasma cell-free DNA (cfDNA) as a minimal-invasive biomarker for early cancer detection and cancer treatment responses monitoring.

    Method
    

    Methods: To characterization the baseline data of CIN in cfDNA, 171 plasma samples were collected since June 2017. 35 was from non-cancer individuals. 136 was from cancer patients. cfDNA was extracted and sent to low-coverage genome sequencing on the Illumina X10 platform, followed by chromosomal instability (CIN) analyses by a customized workflow Ultrasensitive Chromosomal Instability Detector (UCAD).

    Result
    

    Results:

    Increased plasma cfDNA CIN was observed along with disease progression. In lung cancer, cfDNA CIN increased along with the development of lesions, from adenocarcinoma in-situ, minimal invasive adenocarcinoma, invasive adenocarcinoma (P=0.034) to relapsed cancer (P<0.01). The sensitivity of early lung cancer detection was 30.7%, 37.5%, 45.5%, 50.0% and 98.1% for AIS, MIA, IAC, SCC and relapsed lung cancer, at a specificity of 75%.

    In primary lung cancer, cfDNA CIN decreased after curative therapies. And cfDNA CIN significantly increased after disease relapsed (P<0.01). And cfDNA levels did not show statistical differences regarding metastases sites.

    Conclusion
    

    Conclusions:

    cfDNA CIN can help early cancer detection and treatment response monitoring.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.